Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rx-to-OTC Switch Interest Explodes Following Deal Activity - Experts

This article was originally published in The Tan Sheet

Executive Summary

Pharmaceutical firms are developing and reshaping their Rx-to-OTC switch strategies to remain competitive in an evolving industry where recent mergers and acquisitions underscore the importance of an OTC presence and switch platform
Advertisement

Related Content

J&J Woes, Pharma Switch Outlook Lead "The Tan Sheet" 2010 Topics
Meda Lands In U.S. OTC Space With Alaven Buy
Crestor Indication Grows User Pool, But Self-Selection Hinders Statin Switch
GSK's Consumer Segment Grows 7% With Heavy Investment In R&D And A&P
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q4 2009
Sanofi Needs Switch Skills To Span Gap Between Rx And OTC Divisions
Sanofi Needs Switch Skills To Span Gap Between Rx And OTC Divisions
Merck Gives Consumer Health Care Division Direct Line To CEO
Pfizer’s Wyeth Buy Rebuilds OTC Switch Potential
Prilosec OTC Approved In 28-, 42-Count Multiple Regimen Sizes

Topics

Advertisement
UsernamePublicRestriction

Register

PS103691

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel